DIFFUSE LARGE B‐CELL LYMPHOMA: REAL‐WORLD CLINICAL EXPERIENCE WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE IN CUBA

Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders. Diffuse large B-Cell Lymphoma (DLBCL) is the most common NHL in adults, it accounts around 30-40% all NHL. Chemoimmunotherapy regimen based on Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) standard care for DLBCL patients. The present study investigated its application real-world clinical practice at single institution Cuba. Data patients diagnosed from treated with R-CHOP January 2008 to June 2019 were retrospectively analyzed. A total 183 (57.4% male, 42.6% female) included, median age 51 years old (range 19–84) 67.2% under 60 years. Extra nodal disease occurred 47.3% cases. Most cases (66.5%) localized stage (I–II). Patients categorized as International Prognostic index (IPI) low 61.3%; low-intermediate 25.2%; high intermediate 11% 2.5%. Revised IPI (R-IPI) categories grouped very good 15.4%, Good 71.0% Poor 13.6%. Radiotherapy was associated 45.4% objective response rate achieved 73.8% (complete [CR] 66.7%). After follow-up 5.7 years, 5 overall survival (OS) 71.4%. OS rates by ˂60 versus ≥60 (74.1% vs. 66.2% p = 0.02), performance status 0-1 2-4 (73.5% 52.9%; 0.042) I–II III-IV (81.2% ˂ 0.001), R-IPI poor (89.8% 74.5% 49.8%; CR No (84.1% 38.8%; 0.001). Multivariate analysis established that category (Hazard Ratio [HR] 2.51; 95% CI 1.14–5.51) achieve complete (HR 6.89; 3.4–13.95) independent favorable risk factors OS. In conclusion, this setting indicated excellent outcomes achieved, similar those reported trials. Keyword: aggressive B-cell non-Hodgkin lymphoma conflicts interests pertinent abstract.